Arbeitsgemeinschaft für Medikamentöse Tumortherapie - AGMT
Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) was established with the objective of getting better results and improved understanding of the treatment of malignant tumors by carrying out independent clinical tests. Since the time it was established, nearly 3000 patients have undergone over 50 clinical trials at 35 hospitals conducted by AGMT all across Austria. Covering the entire Oncology as far as possible is a matter of concern for the AGMT in the process, and this is also reflected in the large number of clinical trials conducted, which are aimed at the treatment of solid tumors as well as heamato-oncological diseases.
Particularly in the field of Oncology, the key to success lies in ongoing advanced development and improvements in the therapies. Clinical trials do justice to this requirement and offer the best treatment available in accordance with the state-of-the-art science to the patients participating in them. The particularly detailed investigations carried out in the course of the clinical trials and the diligent ongoing monitoring of the success of the treatment represents an enhancement of the quality of life for the patients.
Richard Greil, Prof. MD,
CEO AGMT non-profit GmbH
Daniela Wolkersdorfer, PhD
Central Trial Coordinator
Clinical trials for the advancement of modern tumor therapy
In the course of clinical trials, AGMT works together with the most highly qualified specialists of leading institutions in Austria and the neighboring countries. The quality and success of AGMT clinical trials is ensured by associating relevant centers having their focus on Oncology. In order to continue doing justice to our goals, we are constantly expanding our cooperation with those specialists, institutions and study groups who are interested in the same.